Crowdonomics
Emerald Health Bioceuticals Inc.

Reg A+ · Equity · Feb 2020

ClosedReg A+Equity
via the platform · last checked Aug 16, 2026
Raised
$0 / $50M max
0% of ceiling
Investors
—
—
Estimated pre-money
$31.3M
—

Financials disclosed in this offering

FY2018 · hover for source
$654K
−$2.3M
FY2018
RevenueNet income
Metric
FY2018 audited
Income statement
Revenue
$654,493
Cost of goods sold
$486,379
Gross margin
26%
Net income
-$2,330,694
Balance sheet
Cash
$425,698
Accounts receivable
$294,704
Total assets
$2,715,344
Long-term debt
$0
Total liabilities
$7,452,575
Other
Headcount
6

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

1 amendment
  1. Mar 23, 2020
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$31.3M
Price / share$5.00
Shares offered10,000,000

Estimated, not stated: $5.00 × 6,250,000 securities outstanding.

Offering details

Target—
Max$50,000,000
Min investment—
OpenedFeb 18, 2020
Deadline—
Days active2,426

Links & provenance

Source: SEC EDGAR
0001594062-20-000010
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.